Literature DB >> 31628483

Driving mesenchymal transition in glioblastoma.

Michael Platten1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31628483      PMCID: PMC7080218          DOI: 10.1093/neuonc/noz195

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  18 in total

1.  Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.

Authors:  Anoop P Patel; Itay Tirosh; John J Trombetta; Alex K Shalek; Shawn M Gillespie; Hiroaki Wakimoto; Daniel P Cahill; Brian V Nahed; William T Curry; Robert L Martuza; David N Louis; Orit Rozenblatt-Rosen; Mario L Suvà; Aviv Regev; Bradley E Bernstein
Journal:  Science       Date:  2014-06-12       Impact factor: 47.728

2.  NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma.

Authors:  Yifu Song; Yang Jiang; Dongxia Tao; Zixun Wang; Run Wang; Minghao Wang; Sheng Han
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

3.  Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis.

Authors:  Verena Körber; Jing Yang; Pankaj Barah; Yonghe Wu; Damian Stichel; Zuguang Gu; Michael Nai Chung Fletcher; David Jones; Bettina Hentschel; Katrin Lamszus; Jörg Christian Tonn; Gabriele Schackert; Michael Sabel; Jörg Felsberg; Angela Zacher; Kerstin Kaulich; Daniel Hübschmann; Christel Herold-Mende; Andreas von Deimling; Michael Weller; Bernhard Radlwimmer; Matthias Schlesner; Guido Reifenberger; Thomas Höfer; Peter Lichter
Journal:  Cancer Cell       Date:  2019-03-21       Impact factor: 31.743

4.  Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.

Authors:  Eudocia Q Lee; David A Reardon; David Schiff; Jan Drappatz; Alona Muzikansky; Sean A Grimm; Andrew D Norden; Lakshmi Nayak; Rameen Beroukhim; Mikael L Rinne; Andrew S Chi; Tracy T Batchelor; Kelly Hempfling; Christine McCluskey; Katrina H Smith; Sarah C Gaffey; Brendan Wrigley; Keith L Ligon; Jeffrey J Raizer; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2015-01-07       Impact factor: 12.300

5.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.

Authors:  Wolfgang Wick; Susan Dettmer; Anne Berberich; Tobias Kessler; Irini Karapanagiotou-Schenkel; Antje Wick; Frank Winkler; Elke Pfaff; Benedikt Brors; Jürgen Debus; Andreas Unterberg; Martin Bendszus; Christel Herold-Mende; Andreas Eisenmenger; Andreas von Deimling; David T W Jones; Stefan M Pfister; Felix Sahm; Michael Platten
Journal:  Neuro Oncol       Date:  2019-01-01       Impact factor: 12.300

Review 6.  Concepts in glioma immunotherapy.

Authors:  Michael Platten; Lukas Bunse; Wolfgang Wick; Theresa Bunse
Journal:  Cancer Immunol Immunother       Date:  2016-07-26       Impact factor: 6.968

7.  Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.

Authors:  Katherine B Peters; Eric S Lipp; Elizabeth Miller; James E Herndon; Frances McSherry; Annick Desjardins; David A Reardon; Henry S Friedman
Journal:  J Neurooncol       Date:  2017-12-21       Impact factor: 4.130

8.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma.

Authors:  Cyril Neftel; Julie Laffy; Mariella G Filbin; Toshiro Hara; Marni E Shore; Gilbert J Rahme; Alyssa R Richman; Dana Silverbush; McKenzie L Shaw; Christine M Hebert; John Dewitt; Simon Gritsch; Elizabeth M Perez; L Nicolas Gonzalez Castro; Xiaoyang Lan; Nicholas Druck; Christopher Rodman; Danielle Dionne; Alexander Kaplan; Mia S Bertalan; Julia Small; Kristine Pelton; Sarah Becker; Dennis Bonal; Quang-De Nguyen; Rachel L Servis; Jeremy M Fung; Ravindra Mylvaganam; Lisa Mayr; Johannes Gojo; Christine Haberler; Rene Geyeregger; Thomas Czech; Irene Slavc; Brian V Nahed; William T Curry; Bob S Carter; Hiroaki Wakimoto; Priscilla K Brastianos; Tracy T Batchelor; Anat Stemmer-Rachamimov; Maria Martinez-Lage; Matthew P Frosch; Ivan Stamenkovic; Nicolo Riggi; Esther Rheinbay; Michelle Monje; Orit Rozenblatt-Rosen; Daniel P Cahill; Anoop P Patel; Tony Hunter; Inder M Verma; Keith L Ligon; David N Louis; Aviv Regev; Bradley E Bernstein; Itay Tirosh; Mario L Suvà
Journal:  Cell       Date:  2019-07-18       Impact factor: 41.582

Review 9.  Revisiting the Concept of Targeting NFAT to Control T Cell Immunity and Autoimmune Diseases.

Authors:  Jae-Ung Lee; Li-Kyung Kim; Je-Min Choi
Journal:  Front Immunol       Date:  2018-11-27       Impact factor: 7.561

10.  The landscape of the mesenchymal signature in brain tumours.

Authors:  Jinan Behnan; Gaetano Finocchiaro; Gabi Hanna
Journal:  Brain       Date:  2019-04-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.